Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 1.00 |
| ▸ | PARP1 | P09874 | 5/20 | 0.74 |
| ▸ | GRM5 | P41594 | 6/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279903 | 1.00 | PARP10 (1.00) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL12090727 | 0.89 | PARP10 (0.81) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL16561672 | 0.86 | PARP10 (0.76) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL2619126 | 0.85 | PARP10 (1.00) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL31585995 | 0.85 | PARP10 (1.00) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL10190815 | 0.82 | GRM5 (0.78) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL8156296 | 0.82 | PARP10 (1.00) | PARP10PARP11PARP1GRM5PDPK1 | |
| SCHEMBL148819 | 0.81 | PARP10 (0.68) | PARP10PARP11PARP1GRM5 | |
| Ethane SCHEMBL27832823 | 0.79 | PARP10 (0.66) | PARP10PARP11PARP1GRM5 | |
| SCHEMBL23657097 | 0.79 | PARP10 (0.65) | PARP10PARP11PARP1GRM5PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115504986-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4294790-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-4166553-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115504986-A | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-111094250-B | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022178532-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | PARP10 1910/4885PARP11 1414/4885PARP1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.